ET-743 Biosynthetic Gene Cluster Heterologous Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in obtaining sufficient amounts of the chemotherapeutic natural product ET-743, as it is produced in low yields from natural sources and is difficult to culture the uncultivable bacterial symbiont Candidatus Endoecteinascidia frumentensis, hindering the study of its biosynthetic pathways and commercial production.
Innovation Solution
The completion of the ET-743 biosynthetic gene cluster using next-generation sequencing technologies, allowing for the identification of key genes and enzymes involved in its production, which can be expressed in cultivable host organisms to synthesize ET-743 or its intermediates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the uncultivable bacterial symbiont Candidatus Endoecteinascidia frumentensis is used to produce ET-743, then the natural product can be obtained from its biosynthetic pathways, but the inability to culture this organism in the laboratory severely hinders the study and commercial production
Solution Approach 1:
The patent applies the copying principle by transferring the biosynthetic gene cluster of ET-743 from the uncultivable bacterial symbiont into a cultivable host organism. Instead of attempting to culture the original producer, the invention creates a functional copy of the biosynthetic pathway in a host that can be easily grown and manipulated in the laboratory, thereby enabling both study and commercial production of ET-743
Solution Approach 2:
The patent uses a cultivable host organism as an intermediary system. This host acts as a mediator that receives the biosynthetic genes from the uncultivable bacterium and produces the desired compound ET-743. The intermediary host bridges the gap between the genetic capability of the original producer and the practical needs of laboratory cultivation and scale-up
2Quantity of substance
If ET-743 is produced from natural sources, then the compound can be obtained, but it is produced in low yields
Solution Approach 1:
The patent applies preliminary action by first identifying and characterizing the complete biosynthetic gene cluster before attempting production. The invention performs preliminary genetic analysis, sequence determination, and functional characterization of individual genes and domains, which enables subsequent optimized expression in host organisms to achieve high-yield production
Solution Approach 2:
The patent segments the complex biosynthetic pathway into individual genes and functional domains (such as adenylation domains, condensation domains, peptidyl carrier protein domains). This segmentation allows for independent study, optimization, and expression of each component, facilitating improved production efficiency through modular genetic engineering approaches
3Loss of information
If the biosynthetic pathway is studied in the original bacterial symbiont, then the natural production mechanism can be understood, but the uncultivable nature of the organism hinders biochemical experiments
Solution Approach 1:
The patent creates a copy of the biosynthetic system in a cultivable host organism, preserving all the genetic and functional information of the original pathway while enabling easy access for biochemical experiments. The host organism serves as an experimentally accessible replica of the original producer
Solution Approach 2:
The patent enables the host organism to express the biosynthetic genes and produce ET-743 autonomously. The transformed host cells can be grown in standard media, maintained in the laboratory, and used for repeated biochemical studies without requiring the original uncultivable symbiont, making the system self-sufficient for research purposes
Data Source
AI summary
The present disclosure is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention provides polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS-derived drug, the polypeptides encoded by such polynucleotides, expression vectors comprising the polynucleotides, host cells comprising the polynucleotides or expression vectors, and kits comprising a host cell. Also provided is a method for the production of ET-743, the NRPS-derived drug.